ArticleMolecular systems biology2019
CRISPR screens are feasible in TP53 wild-type cells.
Article in Molecular systems biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Targeting synthetic lethality between non-homologous end joining and radiation in very-high-risk medulloblastoma.Cell reports. Medicine · 2025Article
- The CRISPR-Cas revolution in head and neck cancer: a new era of targeted therapy.Functional & integrative genomics · 2025Review
- CRISPR knockout genome-wide screens identify the HELQ-RAD52 axis in regulating the repair of cisplatin-induced single-stranded DNA gaps.Nucleic acids research · 2024Article
- CRISPR knockout genome-wide screens identify the HELQ-RAD52 axis in regulating the repair of cisplatin-induced single stranded DNA gaps.bioRxiv : the preprint server for biology · 2024Article
- A scalable platform for efficient CRISPR-Cas9 chemical-genetic screens of DNA damage-inducing compounds.Scientific reports · 2024Article
- Sex-biased genome-editing effects of CRISPR-Cas9 across cancer cells dependent on p53 status.iScience · 2023Article
- Optimized metrics for orthogonal combinatorial CRISPR screens.Scientific reports · 2023Article
- Article
- TP53-dependent toxicity of CRISPR/Cas9 cuts is differential across genomic loci and can confound genetic screening.Nature communications · 2022Article
- Current and future direction in treatment of HPV-related cervical disease.Journal of molecular medicine (Berlin, Germany) · 2022Review
- Improving Homology-Directed Repair in Genome Editing Experiments by Influencing the Cell Cycle.International journal of molecular sciences · 2022Review
- BIRC2-BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemia.Scientific reports · 2022Article
- CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies.Cancer research · 2022Article
- A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing.Nature communications · 2021Article
- Genome-wide interrogation of gene functions through base editor screens empowered by barcoded sgRNAs.Nature biotechnology · 2021Article
- Paralogous synthetic lethality underlies genetic dependencies of the cancer-mutated geneLife science alliance · 2021Article
- Application of CHyMErA Cas9-Cas12a combinatorial genome-editing platform for genetic interaction mapping and gene fragment deletion screening.Nature protocols · 2021Review
- Loss of the abasic site sensor HMCES is synthetic lethal with the activity of the APOBEC3A cytosine deaminase in cancer cells.PLoS biology · 2021Article
- Discovering and validating cancer genetic dependencies: approaches and pitfalls.Nature reviews. Genetics · 2020Review
- Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A recent study by Haapaniemi et al (2018) reported that intact p53 signaling hampers CRISPR-based functional genomic screens. Brown et al report good performance of genome-scale screens in TP53 wild-type cells and reiterate best practices for CRISPR screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.